Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.66 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.66 |
| ▸ | CTSD | P07339 | 2/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4551069 | 1.00 | BACE1 (0.66) | BACE1BACE2CTSDPTPN1 | |
| SCHEMBL2801424 | 0.96 | BACE1 (0.69) | BACE1BACE2CTSDPTPN1 | |
| SCHEMBL2801988 | 0.96 | BACE1 (0.69) | BACE1BACE2CTSDPTPN1 | |
| SCHEMBL4398394 | 0.96 | BACE1 (0.69) | BACE1BACE2CTSDPTPN1 | |
| SCHEMBL4398402 | 0.96 | BACE1 (0.69) | BACE1BACE2CTSDPTPN1 | |
| SCHEMBL29382122 | 0.95 | BACE1 (0.60) | BACE1BACE2CTSDPTPN1 | |
| SCHEMBL29641835 | 0.93 | BACE1 (0.69) | BACE1BACE2CTSDPTPN1 | |
| SCHEMBL30804672 | 0.90 | BACE1 (0.69) | BACE1BACE2CTSD | |
| SCHEMBL30658562 | 0.89 | BACE1 (0.66) | BACE1BACE2CTSDPTPN1 | |
| SCHEMBL30799944 | 0.88 | PTPN1 (0.69) | BACE1BACE2CTSDPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986694-B1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTHCARE AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2009-03-26 | — | — | US | disclosed |
| EP-1986694-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | Novo Nordisk A/S (DK) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093594-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (DK) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | PTMS, VIP, LNPEP | BACE1 2172/4885BACE2 1764/4885CTSD 1568/4885 |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | PTMS, VIP, LNPEP | BACE1 2172/4885BACE2 1764/4885CTSD 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.